Montelukast Normon (Montelukast)

Montelukast selectively antagonizes the cysteinyl leukotriene receptor CysLT1 on airway smooth muscle and inflammatory cells. By inhibiting leukotrienes D4, E4 and related mediators, it reduces bronchoconstriction, mucus secretion, and eosinophil recruitment, leading to improved airway patency and reduced allergic inflammation.

The specific dose of Montelukast Normon is determined by the prescribing clinician based on the patient’s age, diagnosis, and clinical response. Healthcare professionals follow approved labeling and adjust the regimen as needed for optimal therapeutic effect.

Montelukast is classified as Pregnancy Category B, indicating no evidence of risk in animal studies but limited human data. It may be used during pregnancy only if the potential benefit justifies any potential risk. While it passes into breast milk in small amounts, breastfeeding decisions should be made after weighing maternal benefit against possible infant exposure.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients with aspirin‑exacerbated respiratory disease or those who prefer a once‑daily tablet. Unlike bronchodilators, it does not provide immediate relief of acute bronchospasm but helps control chronic inflammation.

Montelukast Normon tablets should be stored at ambient temperature, below 25 °C. Keep them in the original blister or container, protect from moisture, heat and direct sunlight, and keep out of reach of children.

Montelukast Normon is taken orally, usually once daily in the evening, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious adverse events, though rare, include severe allergic reactions such as anaphylaxis, mood changes including depression or suicidal thoughts, and rare skin disorders like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience rash, swelling, mood disturbances, or any signs of an allergic reaction.

Montelukast is contraindicated in individuals with known hypersensitivity to montelukast or any component of the formulation. Caution is advised for patients with severe hepatic impairment, and it should be avoided in those who require immediate relief of acute bronchospasm, as it does not act as a rescue medication.